We would love to hear your thoughts about our site and services, please take our survey here.
As I said a year or so ago, I have a feeling that 2025 is the year we will see the approval in the US complete and possibly a China at the beginning of 2025. Jim Mellon isn’t investing his millions in here to keep Jamie living he could just move him to another of his companies.
Why the 17% jump today.
I think if Bignose or Italian asked some of their questions to Jim Mellon he would respond. The journey continues.
Maybe time to email Jim Mellon with your thoughts Bignose?
I have sent him a couple of emails but no response from him. Usually very good.
Is the delay’s in the US & China due to Dr Mike Wylie no longer being involved?
They have arrived.
News | Pacific Medical Systems Limited - Deltex's TrueVue™ Oesophageal Doppler Monitoring System - official Asia Launch during the 18th World Congress of Anaesthesiologists 2024
Very happy to be working so closely with Pacific Medical Systems in Asia and looking forward to seeing the business really develop across the region under their management.
Having a great week at Kimes 2024 in Seoul, showcasing the new TrueVue monitor with the Department for Business and Trade. Exhibiting alongside other really innovative UK companies, it's been a hectic week so far, but really interesting, with great feedback.
South Korea is a great place for UK companies to establish their products, within a healthcare system that has the ability to implement new technologies.
A big thanks to the Department for Business and Trade in Seoul for all their help in arranging this. They have done a really great job.
World Congress of Anaesthesia
Great first morning at the WCA in Singapore. Lots of interest in the launch of the new TrueVue monitor and amazing support provided by our Asia partner company Pacific Medical Systems Limited
Is today the day our luck changes…
Date of Board Meeting
The board of directors (the “Board”) of Regent Pacific Group Limited
(the “Company”) announces that a meeting of the Board will be held on
Wednesday, 27 March 2024 for the purpose of, among other matters, approving
the final results of the Company and its subsidiaries for the year ended
31 December 2023 and its publication, and considering the recommendation on
the payment of a final dividend, if any.
I was told soon…
When do we expect our next operational update as it must be soon. What are we hoping for?
Just seen this.
I would say it is going to pick up again soon or a takeover will happen.
ABHI US Accelerator
We are so proud to be partnering with the brilliant team at Deltex Medical, who are leading the way in haemodynamic monitoring. Their innovative Esophageal Doppler Monitoring technology is making waves in #surgery and #criticalcare, providing real-time insights for anaesthetists.
Operational update coming soon…..
Hopefully positive news!
They didn’t know…
We have a product that is required my many men around the world and we have approval for many countries at this moment in time and I know we still have the US and China to come. Why has there never been a marketing campaign?
It would appear that Fortacin was approved in Singapore on the 5th July 2022, was this covered before?
Yes and this was released on 17 April 2023…….
Can’t be long until we get an update….
Jamie Gibson, CEO of the Group, said, “We are delighted with the highly significant and positive
results from the Phase 3 clinical study in China, which reinforces the results from the European
and US Phase 3 clinical studies. This represents an important milestone in the regulatory
submission process in China. We now look forward to our commercial partner in China submitting the New Drug Application (“NDA”) to National Medical Products Administration (“NMPA”) by the
end of Q3 2023 with approval expected 12 months later.”
Jamie Gibson further added, “Senstend has the potential to help about 9 million patients in
China during its first year of launch, growing to over 170 million by the tenth year. Our strong
partner Wanbang Biopharmaceutical, who benefits from being part of the Fosun network. This
company has the marketing expertise established e-commerce platforms and an unrivalled
nationwide logic and distribution through Sinopharm, China’s number one pharmaceutical and healthcare distributor, through its network of hospitals, clinics and pharmacies to ensure the
commercial success of Senstend in China.